tradingkey.logo

Travere Therapeutics Provides Corporate Update And 2026 Outlook

ReutersJan 12, 2026 10:39 PM

- Travere Therapeutics Inc TVTX.O:

  • TRAVERE THERAPEUTICS PROVIDES CORPORATE UPDATE AND 2026 OUTLOOK

  • TRAVERE THERAPEUTICS INC - EXPECTS $127 MILLION U.S. NET PRODUCT SALES IN Q4 2025

  • TRAVERE THERAPEUTICS INC - EXPECTS $410 MILLION U.S. NET PRODUCT SALES FOR 2025

  • TRAVERE THERAPEUTICS INC - TO RESTART PHASE 3 HARMONY STUDY IN Q1 2026

  • TRAVERE THERAPEUTICS INC - PDUFA TARGET DATE FOR FILSPARI APPROVAL IS JANUARY 13, 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI